JPWO2021045159A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021045159A5
JPWO2021045159A5 JP2021544029A JP2021544029A JPWO2021045159A5 JP WO2021045159 A5 JPWO2021045159 A5 JP WO2021045159A5 JP 2021544029 A JP2021544029 A JP 2021544029A JP 2021544029 A JP2021544029 A JP 2021544029A JP WO2021045159 A5 JPWO2021045159 A5 JP WO2021045159A5
Authority
JP
Japan
Prior art keywords
alkyl
haloc
formula
inhibitors
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544029A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021045159A1 (https=
JP7692832B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/033463 external-priority patent/WO2021045159A1/ja
Publication of JPWO2021045159A1 publication Critical patent/JPWO2021045159A1/ja
Publication of JPWO2021045159A5 publication Critical patent/JPWO2021045159A5/ja
Priority to JP2025050332A priority Critical patent/JP2025094217A/ja
Application granted granted Critical
Publication of JP7692832B2 publication Critical patent/JP7692832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544029A 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法 Active JP7692832B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050332A JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019161526 2019-09-04
JP2019161526 2019-09-04
PCT/JP2020/033463 WO2021045159A1 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050332A Division JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Publications (3)

Publication Number Publication Date
JPWO2021045159A1 JPWO2021045159A1 (https=) 2021-03-11
JPWO2021045159A5 true JPWO2021045159A5 (https=) 2023-09-11
JP7692832B2 JP7692832B2 (ja) 2025-06-16

Family

ID=74852211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544029A Active JP7692832B2 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法
JP2025050332A Withdrawn JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050332A Withdrawn JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Country Status (10)

Country Link
US (1) US20230119894A1 (https=)
EP (2) EP4026564A4 (https=)
JP (2) JP7692832B2 (https=)
KR (1) KR20220056219A (https=)
CN (2) CN119113123A (https=)
AU (1) AU2020341926B2 (https=)
BR (1) BR112022003323A2 (https=)
CA (1) CA3151909A1 (https=)
MX (1) MX2022002683A (https=)
WO (1) WO2021045159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
CA3175131A1 (en) * 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure
AU2022340358A1 (en) * 2021-09-02 2024-01-04 Daewoong Therapeutics Inc. Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
WO2025245592A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) * 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
CA3175131A1 (en) * 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Similar Documents

Publication Publication Date Title
JPWO2021045159A5 (https=)
EP2320903B1 (en) THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
AU2012321110B2 (en) Combination treatment
JP2015187125A5 (https=)
JP2012515184A (ja) 大腸がんの治療方法
CN111565716B (zh) 使用地匹福林的方法
JP2017160212A5 (https=)
JP2019517542A5 (https=)
JP2015528471A5 (https=)
JP2009539769A5 (https=)
JP2014502641A5 (https=)
JP2009542699A5 (https=)
JP2009542702A5 (https=)
JP2015528501A5 (https=)
JP2019508476A5 (https=)
US7709504B2 (en) Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
JP2019515909A5 (https=)
JPWO2021187548A5 (https=)
JP2021509395A5 (https=)
EP1274414B1 (en) Nasal administration of metoclopramide for the treatment of gastroparesis
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP2020536048A5 (https=)
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
JP2014534229A5 (https=)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites